Search results
Showing 1 to 4 of 4 results for brolucizumab for treating wet age-related macular degeneration
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.